Obesity Difficult Airway Airway ManagementOBESIALNCT07779343
OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
A study testing Semaglutide (Wegovy) weekly injection, Behavioral Treatment and Weight loss in people with Obesity Difficult Airway Airway Management and Obesity Adult Onset, run by University of Health Sciences, Algeria at 1 site in Algeria.
Trial summary
The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obesity Difficult Airway Airway Management, Obesity Adult Onset, Obesity and Cardiovascular Risk
- What is being tested?
- Semaglutide (Wegovy) weekly injection, Behavioral Treatment and Weight loss
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteAlgeria
- Study dates
- 22 Jan 2026to 23 Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18-65 years
- BMI ≥30 kg/m²
- Written informed consent obtained prior to enrolment
Who cannot join
- Refusal to participate or inability to adhere to follow-up procedures
- Pregnancy at enrolment
- Severe or unstable comorbidities compromising safety or participation, including:
- Recent acute cardiovascular event (<60 days)
- Active malignancy
- Severe unstable organic disease
Show all 13Show fewer
- Previous bariatric surgery
- Obesity pharmacotherapy within the previous 90 days
- Known contraindication to planned therapeutic options
- Severe unstable psychiatric disorders
- Genetic obesity or obesity secondary to uncontrolled endocrine disease
- Pregnancy occurring during follow-up
- Initiation of chronic treatment associated with weight gain
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Mounira Professor Chanegriha. Head of Medicine department, Professor contact
Algeria1 site, 1 recruiting
- Recruiting
Department of Medicine, , Mother and Child Hospital of the Army (MCHA), Algiers University Hospital, Algiers, Algeria.
Algiers, 16000
About this study
The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.
Read the detailed description
OBESIAL is a prospective pragmatic study involving 300 adults with obesity recruited from healthcare facilities in Algeria and followed for 18 months. The primary comparison evaluates outcomes between participants receiving structured multidisciplinary care (G1, n=150) and those receiving non-structured usual care (G2, n=150). The structured pathway includes coordinated medical follow-up, personalised nutritional intervention, adapted physical activity, therapeutic education, and multidisciplinary support.
Within the structured care group, eligible participants will undergo a nested randomised comparison between G1a (lifestyle intervention plus GLP-1 receptor agonist therapy) and G1b (lifestyle intervention alone) to assess the additional effect of GLP-1 receptor agonist treatment.
The primary outcome is the proportion of participants achieving clinically meaningful weight loss (≥5% of initial body weight) at 18 months. Secondary outcomes include changes in body composition, metabolic parameters, treatment response, adherence, and obesity-related outcomes. Longitudinal analyses will be performed using mixed-effects models, while multivariable approaches will explore factors associated with treatment response.
The findings of the OBESIAL study are expected to provide evidence to support the development and optimisation of structured multidisciplinary obesity care pathways in Algeria and may offer relevant insights for other African healthcare systems.
- Conditions
- Obesity Difficult Airway Airway Management, Obesity Adult Onset, Obesity and Cardiovascular Risk, Obesity Type 2 Diabetes Mellitus
- Being tested
- Semaglutide (Wegovy) weekly injection, Behavioral Treatment, Weight loss
- Keywords
- obesity, adult obesity, multidisciplinary care, lifestyle interventions, GLP-1 receptor agonists
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Semaglutide (Wegovy) weekly injectionDrug
Semaglutide (Wegovy®) will be administered as a subcutaneous injection once weekly, with gradual dose escalation according to the recommended dosing schedule for the molecule, up to a target maintenance dose of 2.4 mg once weekly, for 12 months. Semaglutide will be initiated as an adjunct to the structured OBESIAL obesity care pathway in eligible participants randomized to G1a, following a second written informed consent specifically for the pharmacological intervention.
Behavioral TreatmentBehavioural
Also called Structured Care Pathway
Structured care group (G1): Only participants in G1 will undergo the structured care pathway over 18 months.
- Individualised nutritional follow-up adapted to the sociocultural context, consisting of eight sessions, including nutritional education sessions lasting 30 minutes and evaluation sessions lasting 15 minutes.
- An individually tailored physical activity programme based on baseline functional capacity and associated comorbidities. Participants will be encouraged to attend supervised or structured physical activity sessions three times per week, with adjustments according to tolerance and clinical status.
- Psychological support provided according to individual needs, focusing on motivation, emotional eating, barriers to adherence, and behavioural change strategies. The frequency of psychological follow-up will be adapted to patient requirements, reflecting the pragmatic nature of the intervention.
Weight lossOther
Also called Non-Structured Usual Care
The content of care is not standardized or imposed by the OBESIAL protocol and may vary according to local clinical practices, healthcare professionals' habits, available resources, treatment availability, and therapeutic options accessible within the participating healthcare structures. Usual care may include lifestyle and dietary management, physical activity advice or interventions, behavioral support, pharmacological treatment for obesity when clinically indicated and available, including GLP-1 receptor agonist therapy, and other therapeutic options for obesity according to usual clinical practice and individual patient characteristics. Bariatric surgery may also be considered or performed when clinically indicated according to the usual care pathway of the healthcare structure.
| Study group | Role | What they receive |
|---|---|---|
| G1a: Structured Obesity Care + Semaglutide | Experimental | Participants assigned to G1 will initially receive the structured obesity care pathway (OBESIAL) for 18 months. This structured multidisciplinary care includes coordinated medical follow-up, individualized nutritional management adapted to the sociocultural context, a personalized physical activity program, and psychological support according to individual needs. At month 6, the clinical course is reviewed during a multidisciplinary meeting. Bariatric surgery constitutes a therapeutic pathway within the structured care group and not a separate study arm based on clinical indication and patient's wishes. Among participants remaining eligible for pharmacological intervention, an embedded, independent and centralized 1:1 randomization is performed to assign participants to G1a or G1b. The semaglutide intervention is therefore an adjunct to, and not a replacement for, the structured nutritional, physical activity and behavioural interventions provided within the OBESIAL care pathway. Receives: Drug: Semaglutide (Wegovy) weekly injection; Behavioral: Behavioral Treatment |
| G1b : Structured care group / lifestyle intervention alone | Active comparator | Participants assigned to G1 initially receive the structured obesity care pathway (OBESIAL) for 18 months, including coordinated medical follow-up, individualized nutritional management adapted to the sociocultural context, a personalized physical activity program, and psychological support according to individual needs. The structured multidisciplinary assessment involves general practitioners, endocrinologists-diabetologists, dietitians, psychologists and psychiatrists, with referral to organ specialists according to obesity-related comorbidities, including cardiology, pulmonology, gastroenterology, rheumatology and stomatology. Adapted physical activity interventions are supervised by sports medicine physicians or physiotherapists, with functional capacity assessment performed by rehabilitation specialists. Participants randomized to G1b continue the structured obesity care pathway without initiation of pharmacological treatment with semaglutide as part of the study intervention. Receives: Behavioral: Behavioral Treatment |
| G2: Non-structured care group | Active comparator | Participants in G2 receive usual, non-structured obesity care delivered independently of the OBESIAL structured care pathway and outside the study coordinating structure. Care is provided in comparable healthcare structures in order to reflect usual clinical practice while limiting differences related to the type or level of healthcare facility.
The content of care is not standardized or imposed by the OBESIAL protocol and may vary according to local clinical practices, healthcare professionals' habits, available resources, treatment availability, and therapeutic options accessible within the participating healthcare structures The choice, combination, timing and intensity of these therapeutic options are not determined by the OBESIAL study team. Participants therefore remain under the usual care practices of their healthcare structure throughout the study follow-up, without receiving the standardized multidisciplinary structured care pathway implemented in G1. Receives: Other: Weight loss |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Achieving ≥5% Weight Loss at Month 18
Percentage of participants achieving a clinically significant weight loss of at least 5% of initial body weight after 18 months of follow-up, compared between participants receiving the structured multidisciplinary obesity care pathway (G1) and those receiving usual non-structured care (G2), under real-world clinical conditions in adults living with obesity in Algeria.
Measured: 18 months follow-up
Secondary outcomes (7)
Proportion of participants achieving ≥5% weight loss from randomization baseline at Month 18
Percentage of participants randomized to G1a or G1b who achieve a weight loss of at least 5% from body weight at the time of randomization (Month 6) to Month 18.
Measured: From Month 6 to Month 18
Proportion of participants achieving ≥10% weight loss from randomization baseline at Month 18
Percentage of participants randomized to G1a or G1b who achieve a weight loss of at least 10% from body weight at the time of randomization (Month 6) to Month 18.
Measured: From Month 6 to Month 18
Proportion of participants achieving ≥15% weight loss from randomization baseline at Month 18
Percentage of participants randomized to G1a or G1b who achieve a weight loss of at least 15% from body weight at the time of randomization (Month 6) to Month 18.
Measured: From Month 6 to Month 18
Baseline predictors of weight loss response to semaglutide at Month 18
Association between baseline characteristics measured at Month 6 and weight loss response from Month 6 to Month 18 among participants randomized to G1a. Weight loss response will be defined as achieving ≥5%, ≥10%, or ≥15% reduction in body weight from the randomization baseline. Baseline characteristics will include age, sex, body weight, body mass index, waist circumference, body composition, glycemic parameters, lipid parameters, and obesity-related comorbidities.
Measured: From Month 6 to Month 18
Change in glycemic parameters from baseline to Month 18
Changes in fasting plasma glucose and glycated hemoglobin (HbA1c), measured in mmol/L and %, respectively, from baseline (Month 0) to Month 18, comparing participants receiving structured multidisciplinary obesity care (G1) with those receiving usual non-structured care (G2). The evolution of these parameters from Month 6, corresponding to the randomization and initiation of semaglutide in G1a, to Month 18 will also be compared between G1a and G1b to assess the additional effect of semaglutide on glycemic parameters.
Measured: Baseline (Month 0) to Month 18 for the G1 versus G2. Month 6 to Month 18 for the G1a versus G1b
Change in lipid parameters from baseline to Month 18
Changes in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, measured in mmol/L, from baseline (Month 0) to Month 18, comparing participants receiving structured multidisciplinary obesity care (G1) with those receiving usual non-structured care (G2). The evolution of these parameters from Month 6, corresponding to the randomization and initiation of semaglutide in G1a, to Month 18 will also be compared between G1a and G1b to assess the additional effect of semaglutide on lipid parameters
Measured: Baseline (Month 0) to Month 18 for the G1 versus G2.Month 6 to Month 18 for the G1a versus G1b.
Change in body composition from baseline to Month 18
Changes in body fat percentage (%), visceral adipose tissue (VAT) area (cm²), and lean mass index (LMI) (kg/m²) from baseline (Month 0) to Month 18, comparing participants receiving structured multidisciplinary obesity care (G1) with those receiving usual non-structured care (G2). Body composition will be assessed at Months 0, 6, 12, and 18 using bioelectrical impedance analysis and dual-energy X-ray absorptiometry (DXA). Changes in these parameters from Month 6, corresponding to randomization and initiation of semaglutide in G1a, to Month 18 will also be compared between G1a and G1b to assess the additional effect of semaglutide on body composition.
Measured: Months 0, 6, 12, and 18; change from Month 0 to Month 18 for G1 versus G2 and from Month 6 to Month 18 for G1a versus G1b
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start22 Jan 2026
- Primary completion23 Jan 2028 (estimated)
- Study completion23 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity Difficult Airway Airway ManagementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- OBESIAL is a hybrid-design study combining a prospective real-world cohort study with a nested randomized controlled trial. In the first phase, it consists of a prospective non-randomized study comparing, among adults living with obesity in Algeria, a structured obesity care pathway with non-structured usual care in order to evaluate the impact of an integrated multidisciplinary consultation in routine clinical practice. In the second phase, after 6 months of follow-up, a nested randomized controlled trial will be conducted among participants within the structured care pathway who are eligible for pharmacological intervention. This component aims to compare the combination of a GLP-1 receptor agonist with lifestyle interventions versus continuation of lifestyle interventions alone. The total follow-up duration for all participants will be 18 months
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Health Sciences, Algeria
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mounira Chanegriha, Professor, Principal investigator, University of health sciences, Faculty of Medicine, Algiers, Algeria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07779343
- Sponsor's protocol ID
- OBESIAL
- Other IDs
- MCHA-MED-2026/01
- Acronym
- OBESIAL
- Status last verified
- Aug 2026
- First submitted
- 11 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
- ClinicalTrials.gov ID
- NCT07779343
- Acronym / sponsor ID
- OBESIAL / OBESIAL
- Conditions
- Obesity Difficult Airway Airway Management, Obesity Adult Onset, Obesity and Cardiovascular Risk, Obesity Type 2 Diabetes Mellitus
- Keywords
- obesity, adult obesity, multidisciplinary care, lifestyle interventions, GLP-1 receptor agonists
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- University of Health Sciences, AlgeriaUniversity, hospital or other
- Study start
- 22 Jan 2026 (actual)
- Primary completion
- 23 Jan 2028 (estimated)
- Study completion
- 23 Jan 2028 (estimated)
- First posted
- 21 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.
Detailed description
OBESIAL is a prospective pragmatic study involving 300 adults with obesity recruited from healthcare facilities in Algeria and followed for 18 months. The primary comparison evaluates outcomes between participants receiving structured multidisciplinary care (G1, n=150) and those receiving non-structured usual care (G2, n=150). The structured pathway includes coordinated medical follow-up, personalised nutritional intervention, adapted physical activity, therapeutic education, and multidisciplinary support.
Within the structured care group, eligible participants will undergo a nested randomised comparison between G1a (lifestyle intervention plus GLP-1 receptor agonist therapy) and G1b (lifestyle intervention alone) to assess the additional effect of GLP-1 receptor agonist treatment.
The primary outcome is the proportion of participants achieving clinically meaningful weight loss (≥5% of initial body weight) at 18 months. Secondary outcomes include changes in body composition, metabolic parameters, treatment response, adherence, and obesity-related outcomes. Longitudinal analyses will be performed using mixed-effects models, while multivariable approaches will explore factors associated with treatment response.
The findings of the OBESIAL study are expected to provide evidence to support the development and optimisation of structured multidisciplinary obesity care pathways in Algeria and may offer relevant insights for other African healthcare systems.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- OBESIAL is a hybrid-design study combining a prospective real-world cohort study with a nested randomized controlled trial. In the first phase, it consists of a prospective non-randomized study comparing, among adults living with obesity in Algeria, a structured obesity care pathway with non-structured usual care in order to evaluate the impact of an integrated multidisciplinary consultation in routine clinical practice. In the second phase, after 6 months of follow-up, a nested randomized controlled trial will be conducted among participants within the structured care pathway who are eligible for pharmacological intervention. This component aims to compare the combination of a GLP-1 receptor agonist with lifestyle interventions versus continuation of lifestyle interventions alone. The total follow-up duration for all participants will be 18 months
| Arm | Type | Receives |
|---|---|---|
| G1a: Structured Obesity Care + Semaglutide | Experimental | Drug: Semaglutide (Wegovy) weekly injection, Behavioral: Behavioral TreatmentParticipants assigned to G1 will initially receive the structured obesity care pathway (OBESIAL) for 18 months. This structured multidisciplinary care includes coordinated medical follow-up, individualized nutritional management adapted to the sociocultural context, a personalized physical activity program, and psychological support according to individual needs. At month 6, the clinical course is reviewed during a multidisciplinary meeting. Bariatric surgery constitutes a therapeutic pathway within the structured care group and not a separate study arm based on clinical indication and patient's wishes. Among participants remaining eligible for pharmacological intervention, an embedded, independent and centralized 1:1 randomization is performed to assign participants to G1a or G1b. The semaglutide intervention is therefore an adjunct to, and not a replacement for, the structured nutritional, physical activity and behavioural interventions provided within the OBESIAL care pathway. |
| G1b : Structured care group / lifestyle intervention alone | Active comparator | Behavioral: Behavioral TreatmentParticipants assigned to G1 initially receive the structured obesity care pathway (OBESIAL) for 18 months, including coordinated medical follow-up, individualized nutritional management adapted to the sociocultural context, a personalized physical activity program, and psychological support according to individual needs. The structured multidisciplinary assessment involves general practitioners, endocrinologists-diabetologists, dietitians, psychologists and psychiatrists, with referral to organ specialists according to obesity-related comorbidities, including cardiology, pulmonology, gastroenterology, rheumatology and stomatology. Adapted physical activity interventions are supervised by sports medicine physicians or physiotherapists, with functional capacity assessment performed by rehabilitation specialists. Participants randomized to G1b continue the structured obesity care pathway without initiation of pharmacological treatment with semaglutide as part of the study intervention. |
| G2: Non-structured care group | Active comparator | Other: Weight lossParticipants in G2 receive usual, non-structured obesity care delivered independently of the OBESIAL structured care pathway and outside the study coordinating structure. Care is provided in comparable healthcare structures in order to reflect usual clinical practice while limiting differences related to the type or level of healthcare facility. The content of care is not standardized or imposed by the OBESIAL protocol and may vary according to local clinical practices, healthcare professionals' habits, available resources, treatment availability, and therapeutic options accessible within the participating healthcare structures The choice, combination, timing and intensity of these therapeutic options are not determined by the OBESIAL study team. Participants therefore remain under the usual care practices of their healthcare structure throughout the study follow-up, without receiving the standardized multidisciplinary structured care pathway implemented in G1. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18-65 years
- BMI ≥30 kg/m²
- Written informed consent obtained prior to enrolment
Key exclusion criteria (13 listed)
- Refusal to participate or inability to adhere to follow-up procedures
- Pregnancy at enrolment
- Severe or unstable comorbidities compromising safety or participation, including:
- Previous bariatric surgery
- Obesity pharmacotherapy within the previous 90 days
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Semaglutide (Wegovy) weekly injectionSemaglutide (Wegovy®) will be administered as a subcutaneous injection once weekly, with gradual dose escalation according to the recommended dosing schedule for the molecule, up to a target maintenance dose of 2.4 mg once weekly, for 12 months. Semaglutide will be initiated as an adjunct to the structured OBESIAL obesity care pathway in eligible participants randomized to G1a, following a second written informed consent specifically for the pharmacological intervention. | Drug | G1a: Structured Obesity Care + Semaglutide |
| Behavioral TreatmentAlso: Structured Care PathwayStructured care group (G1): Only participants in G1 will undergo the structured care pathway over 18 months. * Individualised nutritional follow-up adapted to the sociocultural context, consisting of eight sessions, including nutritional education sessions lasting 30 minutes and evaluation sessions lasting 15 minutes. * An individually tailored physical activity programme based on baseline functional capacity and associated comorbidities. Participants will be encouraged to attend supervised or structured physical activity sessions three times per week, with adjustments according to tolerance and clinical status. * Psychological support provided according to individual needs, focusing on motivation, emotional eating, barriers to adherence, and behavioural change strategies. The frequency of psychological follow-up will be adapted to patient requirements, reflecting the pragmatic nature of the intervention. | Behavioural | G1a: Structured Obesity Care + Semaglutide, G1b : Structured care group / lifestyle intervention alone |
| Weight lossAlso: Non-Structured Usual CareThe content of care is not standardized or imposed by the OBESIAL protocol and may vary according to local clinical practices, healthcare professionals' habits, available resources, treatment availability, and therapeutic options accessible within the participating healthcare structures. Usual care may include lifestyle and dietary management, physical activity advice or interventions, behavioral support, pharmacological treatment for obesity when clinically indicated and available, including GLP-1 receptor agonist therapy, and other therapeutic options for obesity according to usual clinical practice and individual patient characteristics. Bariatric surgery may also be considered or performed when clinically indicated according to the usual care pathway of the healthcare structure. | Other | G2: Non-structured care group |
Primary outcome
Percentage of Participants Achieving ≥5% Weight Loss at Month 18
Time frame: 18 months follow-up
Percentage of participants achieving a clinically significant weight loss of at least 5% of initial body weight after 18 months of follow-up, compared between participants receiving the structured multidisciplinary obesity care pathway (G1) and those receiving usual non-structured care (G2), under real-world clinical conditions in adults living with obesity in Algeria.
7 secondary outcomes
Proportion of participants achieving ≥5% weight loss from randomization baseline at Month 18
Time frame: From Month 6 to Month 18
Proportion of participants achieving ≥10% weight loss from randomization baseline at Month 18
Time frame: From Month 6 to Month 18
Proportion of participants achieving ≥15% weight loss from randomization baseline at Month 18
Time frame: From Month 6 to Month 18
Baseline predictors of weight loss response to semaglutide at Month 18
Time frame: From Month 6 to Month 18
Change in glycemic parameters from baseline to Month 18
Time frame: Baseline (Month 0) to Month 18 for the G1 versus G2. Month 6 to Month 18 for the G1a versus G1b
Change in lipid parameters from baseline to Month 18
Time frame: Baseline (Month 0) to Month 18 for the G1 versus G2.Month 6 to Month 18 for the G1a versus G1b.
Change in body composition from baseline to Month 18
Time frame: Months 0, 6, 12, and 18; change from Month 0 to Month 18 for G1 versus G2 and from Month 6 to Month 18 for G1a versus G1b
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Obesity Difficult Airway Airway Management
Not yet recruitingObservational study
Prediction of Difficult Mask Ventilation in Obese Population Undergoing Emergency Surgery
Difficult Airway Management
Not yet recruitingObservational study
Evaluation of Anterior Neck Ultrasound in Predicting Difficult Airway in Obese Patients
Ultrasonography, Airway Management
Enrolling by invitation
Videolaryngoscopes in the Morbidly Obese
Obesity Difficult Airway Airway Management
RecruitingObservational study
AI-Based Prediction of Difficult Airway in Bariatric Surgery
Obesity Difficult Airway Airway Management
Not yet recruitingObservational study
Effect Of Left Head Rotation On Glottic View During Video Laryngoscopy In Obese Adults
Difficult Airway, Obesity Difficult Airway Airway Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mounira Professor Chanegriha. Head of Medicine department, Professor contact
Mounira Chanegriha, Professor principal investigator
University of health sciences, Faculty of Medicine, Algiers, Algeria
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Semaglutide (Wegovy) weekly injection, Behavioral Treatment and Weight loss in people with Obesity Difficult Airway Airway Management and Obesity Adult Onset, run by University of Health Sciences, Algeria at 1 site in Algeria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Algeria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mounira Professor Chanegriha. Head of Medicine department, Professor (+21321905656 ext. 3012, m.chanegriha@univ-alger.dz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Achieving ≥5% Weight Loss at Month 18 (time frame: 18 months follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.